New insider activity at Guardant Health ( (GH) ) has taken place on September 11, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Co-CEO Helmy Eltoukhy has recently sold 300,000 shares of Guardant Health stock, amounting to a substantial transaction worth $17,834,585.
Recent Updates on GH stock
Guardant Health’s stock experienced notable fluctuations following the release of its Shield V2 algorithm data, which showed a slight improvement in overall sensitivity to 84% from 83%, but fell short of more optimistic expectations. Despite this, BTIG raised its price target for Guardant Health, citing the company’s pioneering role and leadership in liquid biopsy as reasons for optimism. The stock’s decline of 7% was attributed to mixed reactions to the Shield V2 data, with some analysts suggesting the market reaction was overdone. Additionally, Guardant Health announced a strategic agreement with LabFlorida/SunDx Labs to distribute its FDA-approved blood test for colorectal cancer screening in senior living communities, further solidifying its market position.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
Guardant Health’s overall stock score is driven by strong technical indicators and a positive earnings call, which highlight significant revenue growth and improved margins. However, financial performance and valuation concerns due to ongoing losses and negative equity weigh down the score.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
YTD Price Performance: 78.06%
Average Trading Volume: 2,468,850
Technical Sentiment Signal: Buy
Current Market Cap: $7.05B